Vikram Arya
Overview
Explore the profile of Vikram Arya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Choi S, Arya V, Reynolds K
Clin Pharmacol Ther
. 2021 Mar;
109(4):810-812.
PMID: 33715164
No abstract available.
12.
Arya V, Venkatakrishnan K
J Clin Pharmacol
. 2020 Nov;
60 Suppl 1:S7-S11.
PMID: 33205427
No abstract available.
13.
Ren Y, Golding A, Sorbello A, Ji P, Chen J, Saluja B, et al.
J Clin Pharmacol
. 2020 May;
60(8):954-975.
PMID: 32469437
This literature review aims to provide a comprehensive current summary of the pathogenesis, clinical features, disease course, host immune responses, and current investigational antiviral and immunomodulatory pharmacotherapies to facilitate the...
14.
Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2020 May;
9(6):310-321.
PMID: 32441889
Creatinine is the most common clinical biomarker of renal function. As a substrate for renal transporters, its secretion is susceptible to inhibition by drugs, resulting in transient increase in serum...
15.
Scotcher D, Arya V, Yang X, Zhao P, Zhang L, Huang S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2020 May;
9(5):282-293.
PMID: 32410382
Creatinine is widely used as a biomarker of glomerular filtration, and, hence, renal function. However, transporter-mediated secretion also contributes to its renal clearance, albeit to a lesser degree. Inhibition of...
16.
Sampson M, Troy S, Belew Y, Arya V, Struble K
Curr Opin HIV AIDS
. 2019 Sep;
15(1):61-65.
PMID: 31483323
Purpose Of Review: Outline some regulatory considerations and scientific challenges related to the development of long-acting antiretrovirals (ARVs) for the treatment and prevention of HIV-1 infection. Recent Findings: Poor adherence...
17.
Boyd S, Sampson M, Viswanathan P, Struble K, Arya V, Sherwat A
AIDS
. 2019 Apr;
33(6):1089-1093.
PMID: 30946163
: Product labels for cobicistat with atazanavir or darunavir, and for elvitegravir/cobicistat/emtricitabine/tenofovir (alafenamide or disoproxil fumarate) were recently updated to state that these products are not recommended for initiation during...
18.
Zhou T, Arya V, Zhang L
J Clin Pharmacol
. 2019 Mar;
59(8):1049-1060.
PMID: 30924955
The evaluation of potential of a new molecular entity (NME) to inhibit P-glycoprotein (P-gp) in vivo is an integral part of drug development and is recommended by regulatory agencies. In...
19.
Chu X, Liao M, Shen H, Yoshida K, Zur A, Arya V, et al.
Clin Pharmacol Ther
. 2018 Oct;
104(5):836-864.
PMID: 30347454
Drug transporters can govern the absorption, distribution, metabolism, and excretion of substrate drugs and endogenous substances. Investigations to examine their potential impact to pharmacokinetic (PK) drug-drug interactions (DDIs) are an...
20.
Lee S, Arya V, Yang X, Volpe D, Zhang L
Adv Drug Deliv Rev
. 2017 Aug;
116:100-118.
PMID: 28760687
Transporters govern the access of molecules to cells or their exit from cells, thereby controlling the overall distribution of drugs to their intracellular site of action. Clinically relevant drug-drug interactions...